Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13D Filing (0001193125-20-115197)

NAME OF REPORTING PERSONS

Ampersand 2018 Limited Partnership

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) ☐ (b) ☐

SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

AF

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

☐

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

Accession Number:: 0001193125-20-115197
Form Type:: 13D Filing
Publication Date:: 2020-04-22 17:40:57

Filed By:: Ampersand 2018 Limited Partnership
Company:: Interpace Biosciences Inc. (NASDAQ:IDXG)
Filing Date:: 2020-04-23
SEC Url:: 13D Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Ampersand	4,666,666	4,666,666	4,666,666	39. 3 %
AMP-18 Management Company Limited Partnership	4,666,666	4,666,666	4,666,666	39. 3 %
AMP-18 MC	4,666,666	4,666,666	4,666,666	39. 3 %

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

INTERPACE BIOSCIENCES, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

46062X303

(CUSIP Number)

Ampersand 2018 Limited Partnership

AMP-18 Management Company Limited Partnership

AMP-18 MC LLC

55 William Street, Suite 240

Wellesley, MA 02481

Telephone: (781) 239-0700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 7, 2020

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


	SCHEDULE 13D

CUSIP No. 46062X303		Page 2 of 5 Pages

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

4,666,666 (1)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

4,666,666 (1)

(1)

Evidenced by 28,000 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the “Series B”), of Interpace Biosciences, Inc. (the “Issuer”). The Series B is convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the “Common Stock”), equal to the initial stated value per Series B share of $1,000 divided by an initial conversion price of $6.00 per share and then multiplied by the number of shares of Series B to be converted.


(2)	This percentage (a) is calculated based upon 4,043,673 shares of Common Stock outstanding as of April 17, 2020, as disclosed in the Annual Report on Form 10-K for the year ended December 31, 2019 filed by the Issuer on April 22, 2020 and (b) assumes the conversion of all47,000 outstanding shares of Series B into an aggregate of 7,833,334shares of Common Stock.


	SCHEDULE 13D

CUSIP No. 46062X303		Page 3 of 5 Pages

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

4,666,666 (1)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

4,666,666 (1)

(1)

Evidenced by 28,000 shares of Series B. The Series B is convertible from time to time, at the option of the holder thereof, into a number of shares of Common Stock equal to the initial stated value per Series B share of $1,000 divided by an initial conversion price of $6.00 per share and then multiplied by the number of shares of Series B to be converted.


(2)	This percentage (a) is calculated based upon 4,043,673 shares of Common Stock outstanding as of April 17, 2020, as disclosed in the Annual Report on Form 10-K for the year ended December 31, 2019 filed by the Issuer on April 22, 2020 and (b) assumes the conversion of all 47,000 outstanding shares of Series B into an aggregate of 7,833,334 shares of Common Stock.


	SCHEDULE 13D

CUSIP No. 46062X303		Page 4 of 5 Pages

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

SHARED VOTING POWER

4,666,666 (1)

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

4,666,666 (1)

(1)


(2)	This percentage (a) is calculated based upon 4,043,673 shares of Common Stock outstanding as of April 17, 2020, as disclosed in the Annual Report on Form 10-K for the year ended December 31, 2019 filed by the Issuer on April 22, 2020 and (b) assumes the conversion of all 47,000 outstanding shares of Series B into an aggregate of 7,833,334 shares of Common Stock.

Item 1.

Security and Issuer

This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) supplements and amends the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on July 25, 2019, as amended by Amendment No. 1 thereto, filed with the SEC on January 17, 2020 (as amended by Amendment No. 1, the “Prior Statement” and, as supplemented and amended by this Amendment No. 2, the “Statement”). Capitalized terms used but not otherwise defined herein have the meanings set forth in the Prior Statement. Except as specifically supplemented and amended by this Amendment No. 2, items in the Prior Statement remain unchanged.

This Amendment No. 2 is being filed to report that, on April 7, 2020, the Issuer and Ampersand 2018 Limited Partnership, a Delaware limited partnership (“Ampersand”) entered into a Support Agreement (the “Support Agreement”) as further discussed below under Item 6.

Item 5.

Interest in Securities of the Issuer

Item 5(b) of the Prior Statementis hereby amended and supplemented to include the following:

(b) The information set forth or incorporated in Item 6 of this Amendment No. 2 is incorporated by reference in its entirety into this Item 5(b).

Item 6.

Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer

Item 6 of the Prior Statement is hereby amended and supplemented to include the following:

On April 7, 2020, the Issuer and Ampersand entered into the Support Agreement pursuant to which Ampersand consented to, and agreed to vote (by proxy or otherwise), all shares of Series B registered in its name or beneficially owned by it and/or over which it exercises voting control asof the date of the Support Agreement and any other shares of Series B legally or beneficially held oracquired by Ampersand after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Issuer as determinedby the Issuer’s Board of Directors. For purposes of the Support Agreement, “Fundamental Action” means any action proposed to be taken by the Issuer and set forth in Section 4(d)(i),4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation or Section 8.5.1.1,8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement.

The foregoing description of the Support Agreement is qualified in its entirety by reference to the full text of the Support Agreement, which is filed as Exhibit 2to this Amendment No. 2 and incorporated herein by reference in its entirety.

Item 7.

Materials to Be Filed as Exhibits

Exhibit		Description

1.		Joint Filing Agreement among Ampersand, AMCLP and AMCLLC (incorporated by reference to Exhibit 1 to the Schedule 13D filed by Ampersand 2018 Limited Partnership on July 25, 2019).

2.		Support Agreement, dated April 7, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc.

SIGNATURE

After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: April 22, 2020

	Ampersand 2018 Limited Partnership

	By: AMP-18 Management Company Limited Partnership, its General Partner

	By: AMP-18 MC LLC, its General Partner

	By:	/s/ Dana L. Niles
		Name: Dana L. Niles
		Title: Chief Operating Officer



	AMP-18 Management Company Limited Partnership

	By: AMP-18 MC LLC, its General Partner

	By:	/s/ Dana L. Niles
		Name: Dana L. Niles
		Title: Chief Operating Officer



	AMP-18 MC LLC

	By:	/s/ Dana L. Niles
		Name: Dana L. Niles
		Title: Chief Operating Officer